HRS-1167

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Fudan University

Conditions

Advanced Solid TumorsBRCA-Mutated Breast CarcinomaHER2-negative Breast Cancer

Phase 1

Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

RecruitingNCT05473624

Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumors

Start: 2022-08-23End: 2026-12-31Target: 153Updated: 2025-04-15

Phase 2

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

RecruitingNCT06516289

Fudan UniversityBRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer

Start: 2024-09-30End: 2027-06-30Target: 130Updated: 2024-12-12

Related Papers

A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2024-06-015 citations